P2Y12受体对手通过抑制DNA修复来降低B16黑色素瘤的辐射抵抗力.
Yuma Mizoguchi1, Natsuki Mori1, Kazuki Kitabatake1
1Department of Radiation Biosciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 6-3-1 Niijuku, Katsushika-ku, Tokyo 125-8585, Japan.
Biological & pharmaceutical bulletin
|November 19, 2025
概括
P2Y12受体对手可以通过抑制癌细胞DNA修复来增强放射治疗. 这种抑制DNA损伤反应 (DDR) 增加了癌细胞死亡,并改善了抗瘤效应,表明它们作为放射敏感剂的潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 辐射疗法 辐射疗法
背景情况:
- 癌细胞修复由辐射诱导的DNA双链断裂 (DSB),导致放射电阻.
- 抑制DNA修复机制提供了一种提高放射治疗疗效的策略.
研究的目的:
- 研究P2Y12受体在小鼠B16黑色素瘤细胞的放射电阻中的作用.
- 评估P2Y12受体对抗剂作为潜在的放射敏感剂.
主要方法:
- 在实验室和体内实验中使用小鼠B16黑色素瘤细胞进行实验.
- 使用P2Y12受体对抗剂 (克洛皮多格雷尔,PSB0739) 和激动剂 (ADP) 的治疗.
- 评估DNA损伤反应 (DDR),未修复的DNA部位和玛辐射后的细胞死亡.
- 抑制P2Y12受体和评估分成的辐射效应.
主要成果:
- P2Y12受体对抗剂抑制了DDR,增加了未修复的DNA,并在B16黑色素瘤细胞中增强了辐射诱导的细胞死亡.
- 通过增强DDR,ADP (P2Y12激动剂) 增加了放射电阻.
- 照射后的P2Y12受体淘汰会增加未经修复的DNA和细胞死亡.
- 抑制P2Y12增强了分成辐射的疗效和玛辐射的体内抗瘤效果.
结论:
- P2Y12受体在黑色素瘤的放射电阻中发挥着重要作用.
- P2Y12受体对手通过抑制DNA修复来表现出辐射敏感作用.
- P2Y12受体对抗剂是改善放射治疗结果的有希望的药物.
相关概念视频
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Negative Regulator Molecules
38.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.2K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
The Intrinsic Apoptotic Pathway
8.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.2K
DNA Damage can Stall the Cell Cycle
9.9K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.9K


